Literature DB >> 22931650

[Effect of chidamide on human B lymphoma cell lines and its mechanisms].

Yan-Ying Li1, Yan-Fang Wang, Jing Wang, Xiao-Yan Ke.   

Abstract

This study was aimed to explore the effects of histone deacetylase inhibitor chidamide on the proliferation, apoptosis of B lymphoma cell lines Raji (Burkitt lymphoma), Maver and Z-138 (mantle cell lymphoma) and its mechanisms. Three B lymphoma cell lines were cultured in vitro with different concentrations of chidamide for different time. The cell proliferation was determined by CCK-8 method; the cell apoptosis and mitochondrial membrane potential were analyzed by flow cytometry; the protein levels of histone H3/H4 acetylation in cells and the activity of caspase-3 were detected by Western blot. The results showed that chidamide inhibited the proliferation of 3 B lymphoma cell lines in time- and concentration-dependent manners, especially in Z-138 cell line earlier and faster; chidamide could induce cell apoptosis and decline of mitochondrial membrane potential, which was more sensitive in Maver and Z-138 cells than that in Raji cells. Chidamide could elevate the histone H3/H4 acetylation level in 3 B lymphoma cell lines and the activity of caspase-3 in Maver and Z-138 cells. It is concluded that chidamide can inhibit proliferation of B lymphoma cell lines and promote cell apoptosis, the increase of histone H3/H4 acetylation induced by chidamide, triggering of mitochondrial pathway and activation of caspase-3 may be considered as possible mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931650

Source DB:  PubMed          Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi        ISSN: 1009-2137


  3 in total

1.  Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.

Authors:  Ningning Zhang; Caixia Liang; Wenya Song; Dan Tao; Jiarui Yao; Shuai Wang; Li Ma; Yuankai Shi; Xiaohong Han
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

2.  Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway.

Authors:  Jing Liu; Na Lv; Lei Zhou; Yan Li; Li Yu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

3.  Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.

Authors:  Shaoxuan Hu; Dongmei Zou; Daobin Zhou; Yan Zhang; Wei Wang; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.